How much revenue does Jacobio-b make?

Jacobio-b reported 53.53 million CNY in revenue for fiscal year 2025, down 65.6% from 155.71 million CNY in fiscal year 2024.

What companies are similar to Jacobio-b?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include CStone Pharmaceuticals (2616.HK), Alphamab Oncology (9966.HK), Lepu Biopharma Co., Ltd. (2157.HK), Immuneonco-b (1541.HK).

Jacobio-b (1167.HK) Stock

About Jacobio-b

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II tr...

At a glance

Jacobio-b reported revenue of 53.53 million CNY for fiscal year 2025, down 65.6% from fiscal year 2024, and net income of -145.98 million CNY.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.